Ionis Pharmaceuticals Inc (IONS) Chairman Stanley T. Crooke Sells 16,549 Shares

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,549 shares of the firm’s stock in a transaction dated Monday, January 15th. The stock was sold at an average price of $51.76, for a total value of $856,576.24. Following the completion of the transaction, the chairman now directly owns 67,626 shares in the company, valued at $3,500,321.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at $51.61 on Thursday. Ionis Pharmaceuticals Inc has a 12-month low of $37.26 and a 12-month high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. The firm has a market capitalization of $6,420.00, a PE ratio of 368.64 and a beta of 2.86.

Several research analysts have issued reports on the company. Morgan Stanley raised their target price on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 8th. Barclays dropped their target price on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 21st. BMO Capital Markets raised their target price on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. BidaskClub cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.76.

Institutional investors and hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC bought a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at approximately $100,000. Hanseatic Management Services Inc. raised its stake in Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after purchasing an additional 41 shares during the period. Parallel Advisors LLC raised its stake in Ionis Pharmaceuticals by 60.3% during the 3rd quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after purchasing an additional 1,250 shares during the period. The Manufacturers Life Insurance Company raised its stake in Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the period. Finally, WFG Advisors LP raised its stake in Ionis Pharmaceuticals by 77.2% during the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after purchasing an additional 1,655 shares during the period. 91.40% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3143953/ionis-pharmaceuticals-inc-ions-chairman-stanley-t-crooke-sells-16549-shares.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.